INTERCEPT plasma: comparability with conventional fresh-frozen plasma based on coagulation function – an in vitro analysis
- 9 December 2009
- journal article
- research article
- Published by Wiley in Vox Sanguinis
- Vol. 98 (1), 47-55
- https://doi.org/10.1111/j.1423-0410.2009.01224.x
Abstract
No abstract availableKeywords
This publication has 24 references indexed in Scilit:
- Pathogen inactivation: making decisions about new technologiesTransfusion, 2007
- Photochemical treatment of plasma with amotosalen and long‐wavelength ultraviolet light inactivates pathogens while retaining coagulation functionTransfusion, 2006
- Protecting the Blood Supply From Emerging Pathogens: The Role of Pathogen InactivationTransfusion Medicine Reviews, 2005
- Inactivation of viruses in platelet concentrates by photochemical treatment with amotosalen and long‐wavelength ultraviolet lightTransfusion, 2005
- Photochemical treatment of platelet concentrates with amotosalen and long‐wavelength ultraviolet light inactivates a broad spectrum of pathogenic bacteriaTransfusion, 2004
- Emerging Infectious Threats to the Blood SupplyAnnual Review of Medicine, 2004
- Preclinical safety profile of plasma prepared using the INTERCEPT Blood System.Vox Sanguinis, 2003
- Current prevalence and incidence of infectious disease markers and estimated window‐period risk in the American Red Cross blood donor populationTransfusion, 2002
- Fundamentals of the psoralen-based Helinx™ technology for inactivation of infectious pathogens and leukocytes in platelets and plasmaSeminars in Hematology, 2001
- In Vitro Characterization of Solvent/Detergent‐Treated Human Plasma and of Quarantine Fresh Frozen PlasmaVox Sanguinis, 1998